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ABSTRACT  
Diabetes mellitus is a group of metabolic diseases recognized by chronic hyperglycemia resulting from defects in secretion in insulin, insulin 
action or both. There are different types of diabetes like Type 1, type 2, gestational diabetes, secondary diabetes, wolfram syndrome and 
autoimmune polyglandular syndrome. Type 1 and type 2 diabetes are most common type of diabetes. Polydipsia, polyuria, polyphagia, weight 
loss slow wound healing, etc. are common symptoms of Diabetes. Diabetes can be genetic; autoimmune, medical related or even diet related. In 
this article causes and treatment of diabetes is discussed in detail. It includes glimpse of novel technologies like patches, pump and pens, etc. It 
also includes momentary of other treatment like oral and Injectable hypoglycemic drug and surgical treatments. A glance of latest innovation 
for measuring glucose level in body with help of sweat, breath and saliva are explained.  
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Introduction 
Diabetes mellitus is a group of metabolic diseases 
recognized by chronic hyperglycemia resulting from defects 
in secretion in insulin, insulin action or both [1]. .Around 
1500 B.C.E. ancient Egyptians were first to recognized 
Diabetes, it was considered a rare condition in which a 
person urinated excessively and lost weight.Earlier before 
200 years diabetes was not documented and nothing was 
known about mechanism of action. No effective treatment 
was available and it was fatal within weeks to months after 
its diagnosis owning to insulin deficiency.[2] In 200 years, 
major approaches have been done in understanding of the 
underlying causes of diabetes and the approach to its 
prevention and treatment[2]. Diabetes is associated with 
reduction in life expectancy but outlook of disease has 
changed and patients lead active and productive life’s for 
many years after diagnosis. Now a daysmany therapies are 
available for treating hyperglycemia and its complications 
but pathway to its cure has remained elusive.  Since 1923, 10 
scientists have won Nobel Prize for diabetes related 
investigations[2]. 
Causes of diabetes [3] 
Main causes of diabetes are complex and cases with one of 
the two processes; 
1. Due to metabolism: - Body ability to use insulin can be 
impaired due to lifestyle factors like overeating, physical 
inactivity and obesity. This is called insulin resistance. 
Genetics, family history and age can be included in 
uncontrollable risk factors. 
Metabolic form of diabetes includes A. Type 2 diabetes and 
B. Gestational diabetes 
2. Autoimmune: -Insulin-producing beta cells of the 
pancreas can destroyed mistakenly by body immune system. 
Causes of autoimmune diabetes are poorly understood but 
family history and genetics play a role. It includes A. Type 1 
Diabetes 
Diabetes is considered as a multi-factorial, involving risk 
factors and predisposing conditions. In many cases 
environment or genetics may contribute to aperson’s 
diabetes. Autoimmune diabetes is more common in white 
people but type 2 and gestational diabetes is common 
among other ethnicities. 
Prediabetes, insulin resistance and metabolic syndrome are 
strong risk factors. Major causes of diabetes are:- 
1. Genetics and family history: - Maturity-onset diabetes 
of young (MODY) and Wolfram syndrome can be 
caused by certain genes. 
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2. Weight and Body type: - Obesity and overweight are 
leading factors in type 2 diabetes, Excess fat around the 
abdomen enhances the insulin resistance and 
metabolic syndrome. 
Sufferers of type 1 diabetes are of normal weight but recent 
research indicates the development of type 1 diabetes 
due to obesity.  
3. Level of physical activity: - Epidemics of obesity and 
diabetes is blamed due to lack on regular exercise. 
4. Diet: - Development of diabetes due to the impact of 
diet is controversial. Studies show that heavy 
consumption of soft drink and other simple 
carbohydrates to risk of metabolic diabetes. Foods 
which have low glycemic index to reduced risk.  
5.  Other diseases: - High blood pressure, hyperlipidemia, 
polycystic ovarian syndrome, asthma and sleep apnea 
like medical conditions have been linked to type 2 
diabetes. Type 1 diabetes have been linked to celiac 
disease (gluten intolerance) and other diseases. Many 
diseases may cause secondary diabetes include 
pancreatitis, hemochromatosis, Cushing’s disease and 
acromegaly, Down syndrome etc. 
6. Medical Treatment: - Secondary diabetes may result 
due to hormonal therapies, icatio like diuretics, beta 
blockers, immunosuppressive etc. Drugs like 
pentamidine(for pneumonia) and L-asparaginase have 
been connected with type 1 diabetes. 
7. Smoking: - Cigarette smoking is factor for type 2 
diabetes. 
8.  Alcohol :-  It is risk factor for diabetes 
Types of Diabetes.[3] 
Various type of diabetes are known to man and some it are 
mentioned below:- 
1. Type 1 diabetes: - In the insulin making beta cells of 
pancreases are mistakenly destroyed by our body our 
immune mistake. This an auto immune diseases. Its 
development is quicker than any other from of 
diabetes. Children, adolescent and young adult are 
usually diagnosed. Insulin must be administer 
regularly to survive. 
Type 1 diabetes used to be called juvenile diabetes and 
insulin-dependent diabetes mellitus (IDDM). These are not 
accurate because other form of diabetes can be developed by 
children and adults can develop type 1 diabetes and insulin 
therapy is required for other forms of diabetes. 
Latent autoimmune diabetes of adulthood (LADA) is 
variation of type 1 diabetes after usually occurs later in life 
after 30 years. 
2. Type 2 diabetes: -Metabolic disorder involving insulin 
resistance and excess weight. In this type of diabetes 
insulin is initially produced by pancreases but body 
has trouble using this glucose controlling hormone. 
Ultimately enough insulin is produced to respond to 
body requirements. According to the international 
Diabetes Federation, type 2 diabetes accounts for 85% 
to 90% in developed nation and more number of cases 
in developing nation. Type 2 diabetes is most common 
form of diabetes. 
Development of diabetes may take decades or years. It is 
usually preceded by prediabetes, in which blood sugar is 
above normal but not high enough for diagnosis of diabetes. 
Diabetes prevention program and other research programs 
have demonstrated that escalation of prediabetes to the type 
2 diabetes can be delayed by losing weight by diet and 
proper exercise. 
Type 2 diabetes used to be called adult-onset diabetes and 
non-insulin dependent diabetes mellitus (NIDDM). This 
terms are not correct because children can develop this 
disease and some people may require insuli9 therapy. 
3. Gestational Diabetes: - A temporary metabolic disorder 
that can develop in non-diabetic women during 
pregnancy, usually in third trimester. Family history of 
diabetes, excess weight and hormonal changes 
contribute to this diabetes. According to American 
diabetes Association about 4% of pregnant women 
develop gestational diabetes. Preeclampsia, premature 
delivery, oversized infant (macrosomia) and jaundice 
and breathing problem in occur in infant and mother 
may suffer some problem due to gestational diabetes. 
This disease ends with pregnancy but child and mother 
are at risk of developing type 2 diabetes later in life. 
4. Secondary Diabetes: - Diabetes caused by another 
condition. Pancreatitis, cystic fibrosis, Down syndrome 
and hemochromatosis to medical treatment including 
corticosteroids, other immunosuppressive, diuretics 
and pancreatectomy are some of many potential 
sources of secondary diabetes. An uncommon disease 
caused by a genetic defeat inherited from a parent, it is 
known as Maturity-onset diabetes of young (MODY). 
Generallydiagnosed by the age of 25, in people of 
normal weight. MODY may be classified in type2 
diabetes or secondary diabetes but considered a 
separate condition. 
5. Wolfram Syndrome: - A genetic disorder that involves 
insulin-dependent diabetes, vision problems, deafness 
and diabetes insipidus. 
6. Autoimmune polyglandular syndrome (APS):- Group of 
autoimmune endocrine diseases. Two of the three 
forms of this syndrome is features in type 1. Unstable 
diabetes, also known as brittle or labile diabetes, is 
term used to identify any case of poorly controlled 
diabetes regardless of type. Diabetes mellitus (sugar 
diabetes) involve all these condition. Water diabetes 
(Diabetes insipidus) is an endocrine disorder in which 
kidney release too much water. 
Signs and symptoms of diabetes: -[3]  
Sometimes no symptoms are experienced in some cases and 
diabetes may go undetected because its symptoms many 
attribute to another to many other causes. 
Some symptoms and signs of diabetes include:- 
- Polydipsia (Excessive thirst) 
- Polyuria (Excessive urination) and dehydration 
- Polyphagia (Excessive hunger or appetite) 
- Unexplained weight loss 
- Blurred vision, nearsightedness and other vision 
disorders 
- Frequent infection like skin infection, thrush, gingivitis, 
urinary tract infections and yeast infection 
- Slow healing of sores 
- Skin problems, such as itchiness or acanthosis 
nigricans 
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- Fatigue, lethargy or drowsiness 
- Shakiness or trembling 
- Mood swings or irritability 
- Dizziness or fainting 
- Numbness, tingling or pain in feet, hands or legs, 
Pathophysiology of diabetes:-  
1. Type 1 diabetes: - it results due to the combination of 
environmental and genetic influences. It develops due 
to destruction of insulin producing beta cells of 
pancreas by body’s immune system. Development of T-
cell dependent autoimmunity in genetically susceptible 
individuals may be triggered by toxins or virus or 
dietary factors. Autoimmunity is manifested by 
detectable antibodies to ICA512/IA-2, insulin 
autoantibody, and glutamic acid decarboxylase. 
Due to slow destruction of beta cells prediabetes may occur 
will develops into DM. Other autoimmune may also occur 
like Hashimoto’s thyroiditis, Addison’s disease and 
myasthenia gravis.[4] 
2. Type 2 diabetes: - Main indicator of type 2 is insulin 
insensitivity because of insulin resistance, declining 
insulin production, and ultimately pancreatic beta-cell 
failure. Due to this glucose transport to liver, muscle 
cells and fat cells is reduced. Hyperglycemia occurs due 
to the increase in breakdown of fat.  Hepatic glucose 
levels and glucagon rise during fasting are not 
depressed with a meal.Hyperglycemia results due to 
inadequate levels of insulin and insulin resistance. A 
large number of individual suffering from type 2 DM 
are obese with central visceral adiposity. Adipose 
tissue plays an important in pathogenesis of type 2 DM. 
Theory used to explain this link is the visceral 
hypothesis giving a key role in elevated non-esterified 
fatty acid concentration, two emerging therapies are 
ectopic fat storage syndrome.[5] 
World scenario of diabetes: - 
It is estimated that 366 million people had DM in 2011, by 
2030 this number will be 522 million. 80% of people with 
dm live in low and middle income countries. Dm caused 4.6 
million deaths in 2011. By year 2030, 439 million would 
have type 2Dm. Majority of DM cases in Africa is on type 2 
with less than 10% of DM cases being type 1. A center for 
diseases control and prevention 2011 reports that Dm 
affects about 25.8 million people in USin 2010 with 90 to 
95% of them being type 2.[5] 
In 2000, India (31.7 million) was the country with highest 
number of DM cases followed by China (20.8 million) with 
US (17.7 million) in second and third place respectively. By 
2030 DM may have affected 79.4 individuals in India, while 
in china 42.3 million and US 30.3 million people may be 
impacted by DM.[6] 
Treatment of Diabetes 
1) Oral hypoglycemic drugs [12] 
 Sulfonylureas: -  Tolubutamide, Glipizide 
 Biguanides: -  Metformin 
 Meglitinidies: -  Repaglidnide 
 Thiazolidinedione: - Rosiglitazone 
 α glycosidase inhibitor: - Acarbose, Voglibose
 
                                                 Table 1: Oral Hypoglycemic Drugs[7] 
Name of Drug Mode of Action 
Daily 
Dose 
Route of 
Administration 
Contraindication Side effect 
Metformin 
activation of AMPK in 
hepatocytes 
0.5-2.5g oral 
factors that 
predispose to lactic 
acidosis 
Nausea, abdominal 
discomfort and 
diarrhea 
Sulphonylurea 
Stimulation of pancreatic 
β-cells 
1mg-0.5g Oral liver disease 
Hyperglycemia, 
Weight gain 
Meglitinidies 
Stimulation of pancreatic 
β-cells 
1.5-
480mg 
Oral 
chronic kidney 
disease 
Hyperglycemia, 
Weight gain 
Voglibose 
they produce 
a reversible inhibition of 
membrane-bound 
intestinal 
alpha-glycoside 
hydrolase enzymes 
50-
100mg 
oral 
chronic 
intestinal disorders 
flatulence, diarrhea 
and abdominal 
pain 
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2) Injectable agents 
Table 2: Injectable Drugs. 
Name of drug Mode of Action 
Daily 
Dose 
Route of 
Administration 
Contraindication Side effect 
Liraglutide [13] 
Increase insulin secretion, 
Decrease in food intake and 
inhibition of post-prandial 
glucagon secretion 
0.6-1.8mg 
daily 
Subcutaneous 
Thyroid cancer and 
Multiple endocrine 
neoplasia 
nausea, vomiting, 
diarrhea, 
pancreatitis, 
hypoglycemia 
Insulin [15] 
Insulin stimulate glucose 
transport across cell 
membrane by ATP dependent 
translocation of glucose 
0.2-1.6 
U/Kg/day 
Subcutaneous 
Salbutamol; Oral 
Contraceptives, etc. 
Hypoglycemia, 
Edema, Allergy 
Dulaglutide [10] 
It reduces rate of absorption 
and reduced renal clearance 
rate. 
0.75-1.5 
mg/week 
Subcutaneous 
Pancreatitis and are 
not approved for use 
in T1DM 
nausea, vomiting 
and diarrhea 
 
3) Metabolic surgery [10] 
When Lifestyle management and medications do not achieve 
desired treatment goals bariatric surgery has emerged as the 
most effective treatment for attending significant and 
durable results.  
Mechanism of action  
the exact mechanism of effect of metabolic surgery on 
diabetes is not fully understood but many factors appear to 
play a role like change in bile acid metabolism, GI tract 
nutrition sensing, glucose utilization, insulin resistance and 
intestinal microbiota. This all factors lead to reduce hip Attic 
glucose production increased tissue glucose uptake improve 
insulin sensitivity and enhance beta cell function.[9] 
Side effects  
Myocardial infraction pulmonary embolism intestinal 
leakage bowel obstruction nutritional deficiency and rarely 
kidney stones alcohol abuse depression and suicide.[9] 
 
 
Novel Technologies 
Painless smart patch: The North Carolina state university 
have designed an insulin delivery devicebased on micro 
needle array patches. It is integrated with hypoxia sensitive 
hyaluronic acid (HSHA) vesicles containing insulin and 
glucose oxidase (GOx). It contains live beta cells and 
deliversinsulin when the level of glucose in blood increases. 
There are glucose responsive vesicles (GRVs)which are 
formed by the combination of HS-HA 2-aminoimidazoles, this 
complex forms theglucose responsive vesicles. Insulin and 
glucose oxidase is entrapped into the vesicles. 
Underhyperglycemic conditions, glucose undergoes 
oxidation catalyzed by GOx and this forms 
amicroenvironment of hypoxia which leads to dissociation of 
the vesicles and release of insulin.[8] 
Advantage 
1. Fast responsiveness and close similarity of 
pharmacokinetic parameters to pancreas 
2. Ease of administration 
3. Biocompatibility 
 
 
Fig 1: - Schematic of the glucose-responsive insulin delivery system using hypoxia-sensitive vesicle-loading MN-array 
patches[8] 
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Fig 2: - Photograph of the smart insulin patch with an MN array 
 
Clicksoft microinjection device: it is a spring loaded micro 
needle intradermal injectionsystem. Patient does not 
experience pain while administering insulin from this 
device. The patient,the micro needles project out of the 
device and pierces into the skin and the drug is passed into 
anultrafine needle in a fine stream of liquid medication from 
the drug chamber into the layers of theskin.[10] 
 
Advantages 
1. It has the proficiency to deliver 100 plus units of insulin in 
a single dose. 
2. It has a faster onset of action when compared to any of the 
rapid acting insulin presentlyavailable in the market. 
3. No refrigeration is required as it is using stabilized insulin. 
4. Cost effective. 
 
 
Fig 3: - Clicksoft Microinjection device with drug chamber[10] 
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Insulin pen: in this system a there is a pen which contains a 
cartridge of insulin and it can beused multiple times a day by 
a single patient using a disposable syringe every time. This 
devicereduces the risk of contamination between the 
patients. There are basically two types of pens thatis 
Prefilled pen and Reusable pen. Prefilled pens are "use and 
throw pen". Reusable pens are thosewhich have replaceable 
cartridges and once the insulin ends up the patient can insert 
a newcartridge. This system is economical but there are 
chances of loss of sterility. Needle is screwedinto the pen, 
then the dose is dialed, then injection is inserted 
subcutaneously and after pressingthe plunger the injection is 
kept inside for 5 sec. Generally, the capacity of these pens is 
1.5ml or3ml. cartridge should be refrigerated and after it is 
inserted into the pen temperature should bemaintained.[8]
 
 
Fig 4: - Insulin pen[8] 
 
V-go: It is a FDA approved device which delivers insulin 
every hour for an interval of 24hours. This system uses the 
patch technology and is non-electric and works without 
batteries ortubing. Vgo uses rapid acting analog insulin. It is 
waterproof. Every 24 hours a new insulincartridge has to be 
placed inside the device.[11] 
 
 
Advantages 
1. Needle phobia is eliminated. 
2. Reduces multiple dose injections. 
3. It can be taken outdoors 
4. Adheres to the skin with colostomy adhesive. 
5. Auto inserts 30 gauze needle that results to minimized 
pain
 
 
Fig 5: - V-Go device[11] 
 
Afrezza Insulin Inhaler: Inhalation is appropriate route for 
the delivery of insulin because alveoli provideslarge surface 
area for rapid absorption of the drug into the blood stream. 
Afrezza is a product usedfor this purpose. It increases the 
absorption of glucose by the skeletal muscle and lessens 
theproduction of hepatic glucose. It is available with 4 and 8 
unit cartridges which is tailored in theinhaler. The content of 
the cartridge comprises of dry powder of insulin which 
becomesaerosolized when the patient breaths through the 
inhaler.[8]
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Fig 6: - Afrezza Pump.[8] 
 
Alginate encapsulated pancreatic islets: Encapsulation of 
pancreatic islets offers an alternative to immunosuppression 
and the capsule act as semipermeable membrane that 
hinders the immune attack of the transplanted cells. 
Capsules are advantages over large device in that they 
provide Rapid diffusions of nutrients as well as oxygen and 
diffusion of insulin out to surrounding environment.  
Capsules reduce the risk of graft failure due to distribution of 
cell in numerous device. The capitals are normally injected 
into the peritoneal cavity where the cell get the access to 
nutrients and oxygen from the surrounding fluid.[16]
 
 
 
Fig 7: - Immune isolation by encapsulation. Demonstration of cells in capsule where nutrients and oxygen can diffuse 
into the capsule. [16] 
 
Diagnostic test for Diabetes [14] 
Table 3: diagnostic test for diabetes 
Test Criteria 
Fasting Plasma Glucose (FPG) ≥126mg/dl 
2-hr plasma glucose (during  oral glucose tolerance test with loading dose of 75g) ≥200mg/dl 
Casual plasma glucose (RPG) ≥200mg/dl 
Glycated hemoglobin (A1C) ≥6.5% 
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Recent patented drugs for the treatment of diabetes [15] 
Table 4: Recent patented drugs. 
Generic/Code Name  Manufacturer Indication Phase 
DPP-4 Inhibitors 
Dutogliptin Phenomix/Forest Laboratories Type 2 diabetes 3 
Linagliptin Boehringer Ingelheim Type 2 diabetes 3 
Melogliptin Glenmark Pharmaceuticals Type 2 diabetes  2 
GLP-1 Analogs 
Albiglutide GSK Type 2 diabetes  2 
Exenatide LAR Amylin/Alkermes/Lilly Type 2 diabetes 3 
Taspoglutide Roche/Ipsen Type 2 diabetes 3 
Biguanides 
Metformin gum/buccal Generex/Fertin Pharma Type 2 diabetes  2 
Thiazolidinedione/PPAR-γ Agonists 
Balaglitazone Dr. Reddy’s Laboratories Type 2 diabetes  3 
Mitoglitazone Metabolic Solutions Development Type 2 diabetes  2 
Netoglitazone Mitsubishi Tanabe Type 2 diabetes  2 
Rivoglitazone Daiichi-Sankyo Type 2 diabetes  3 
Selective Sodium Glucose CoTransporter Inhibitors 
Dapagliflozin AstraZeneca Type 2 diabetes  3 
Remogliflozin GSK/Kissei Type 2 diabetes  2 
Glinides 
Mitiglinide Elixir Pharmaceuticals Type 2 diabetes  3 
Insulin 
Inhaled Technosphere insulin Mankind Type 1 and type 
2 diabetes 
3 
Insulin intranasal Bentley Type 1 and type 
2 diabetes 
2 
Oral HDV insulin Diasome Type 1 and type 
2 diabetes 
2 
Oral insulin spray Generex Type 1 and type 
2 diabetes 
3 
Rapid-acting insulin for 
injection 
Biodel Type 1 and type 
2 diabetes 
3 
Recombinant human 
hyaluroindase for injection 
Halozyme therapeutics Type 1 diabetes 2 
 
Future Prospects for Diabetes monitoring device 
Sweat 
Sweat can be easily accessed and its production can be 
stimulated on demand by Iontophoresis. Placing a sensor in 
close contact with skin sweat samples can be examined 
without contamination.  A healthy person’s glucose level 
were reported between 0.06 and 0.11mM while in case of 
diabetics it was 0.01 and 1mM. [17] 
Wang ET Al have created a device that can be easily 
integrated into individual’s lifestyle this device contains 
lactate biosensor connected on to the one of the nose Bridge 
pad. The device can be coupled by Bluetooth data to remove 
mobile host device for data analysis and visualization. [18]
 
 
Fig 8: - eyeglasses biosensor system 
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Breath 
Breath analysis is one of means for tracking the health status 
of an individual. Metabolism produces volatile organic 
compounds as a by-product they circulate around the body 
and pass over the alveolar interface and exhaled in the 
breath. Nano materials can be incorporated for sensing 
Acetone concentration in breath as an alternative to glucose 
monitoring for diabetes. The sensing units must have a high 
sensitivity to detect volatile organic compounds in Nano 
molar to Pico molar concentration range. [19] 
Jiang and co-workers have reported a breath Acetone 
analyses which can detect Acetone levels in diabetic patient 
but the device requires the control external And Atmosphere 
in order to diagnosis diabetes accurately. [20] 
Saliva 
Saliva is a complex fruit containing many analytes that 
permeate from Blood there by providing a useful insight into 
a person’s emotional, hormonal, metabolic and nutritional 
state. Saliva offers many advantages for diagnosis and 
everyday dental platforms like mouth guards’ dentures as 
well as novel devices like dental tattoos which can be used 
for non-invasive detection of glucose in saliva. [21]
 
 
Fig 9: - Lactate sensing mouth guard[22] 
 
 
Conclusion 
Wearable sensors have the potential to play a major role in 
the continuous and non-invasiveMonitoring of biomarkers 
for diabetes. An important enabling step will be tocreate a 
clear understanding of the relations between the 
diagnostically relevant concentrationsof diseases markers in 
blood compared to other physiological fluids. Existing 
wearable devicessuch as fitness bands and smart watches, 
already dominate the market andprovide an information 
base that can be expanded to disease monitoring or 
diagnosis.However, these wearable technologies canprovide 
additional insights into the wearer’s health and integrated in 
to clinical practices and promote actionable and behavioral 
change. 
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